



November 13, 2019

Novartis Pharma AG/Hexal Biotech ForschungsGmbH

CH-4002, Basel, Switzerland

Reference: EudraCT 2008-004340-37/ Novartis Protocol ID HX575-305

An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfa

Trial HX575-305 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only, was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.